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D uring the last decades many campaigns have raised public awareness of the high inci-dence of cardiovascular disease, while coro-
nary heart disease has been established as the leading 
cause of death in the western world.1 Cardiologists, 
and society as a whole, have experienced tremendous 
advances in our comprehension of cardiovascular risk 
factors and of the mechanisms leading to acute coro-
nary syndromes, as well as huge progress in the inter-
ventional management of atherosclerotic coronary 
artery disease, all of which have greatly improved pa-
tients’ survival and quality of life.2-6
However, people continue to adopt unhealthy 
habits, despite the time and effort spent by health sys-
tems on implementing a healthier life style.7 More-
over, the availability of effective smoking cessation 
programmes is limited in some countries by the size 
of the physician workforce or the lack of trained med-
ical personnel.8 Given these data, Peletidi et al, in 
this issue, provide a literature review of electronic 
databases (Science Direct, Google Scholar, Web of 
Knowledge, Pub Med, NCBI, Scopus, and The Co-
chrane Library) entitled “Smoking cessation support 
services at community pharmacies in the UK: a sys-
tematic review”, in which they describe how medical 
personnel, because of time restrictions, failed to ef-
fectively implement tobacco-use cessation interven-
tions.9 Importantly, based on their systematic review, 
they propose that smoking cessation programs based 
on pharmacy personnel can substantially increase pa-
tients’ awareness of pharmacy-led smoking cessation 
services, improving patient adherence to heath care 
providers’ advice.
Also concerned with nicotine abuse and smoking 
is another review in this issue, entitled “Efficacy and 
safety of electronic cigarette for smoking cessation: a 
critical approach”, by Ioakeimidis et al.10 During the 
last few years, the electronic cigarette has become a 
new trend, which is presented as a means to stop to-
bacco smoking, or as a healthier substitute for ciga-
rette use.11,12 However, as Ioakeimidis et al empha-
sise, limited data exist concerning the long-term ef-
ficacy of electronic cigarettes for smoking cessation, 
while their efficiency in reducing nicotine addiction is 
questioned. In addition, the authors stress the poten-
tial unidentified harmful effects of this type of smok-
ing.
Overall, we have to take note that, as person-
al beliefs and misleading advertisements continue 
to shape public opinion, smoking cessation policies 
have failed, especially in people who have received 
little education and have limited access to health sys-
tem services.13 Moreover, according to the EURO-
ASPIRE III survey, smoking cessation treatment 
is underused14 and smoking therefore continues to 
cause 50% of avoidable deaths in smokers, especially 
deaths of cardiovascular etiology.15
Beyond their straightforward impact on morbidi-
ty and mortality, smoking trends also impose an enor-
mous burden on health care systems. Data from the 
United States have shown that, for every 10 dollars 
spent on healthcare, 90 cents is due to smoking,16 in-
dicating the need to further combat the smoking epi-
demic. These data must be analysed while taking into 
account that health care systems are faced with con-
tinuing reductions in resources and an increase in 
medical expenses, especially for cardiovascular dis-
eases. It is estimated that cardiovascular disease is 
responsible for 17% of expenditure in the United 
States, while the costs of cardiovascular care are ex-
pected to triple by 2030.17
Therefore, primary and secondary prevention 
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measures, and the control of modifiable risk factors 
such as smoking, hypertension, and diabetes melli-
tus, must take priority as the most cost effective medi-
cal approach, especially when it is applied to high risk 
groups.1 Importantly, systematic registration of medi-
cal complications and their management is an alter-
native way of appreciating and reducing health-relat-
ed costs. In the cardiovascular field, cardiac rhythm 
management devices not only offer a substantial im-
provement in the quality of patients’ lives, but also in-
crease their life expectancy.18-20 However, as the use 
of implanted devices increases, it has been recognised 
that the rate of complications is significantly high 
(reaching 12.5% according to some reports) and can 
increase patients’ hospitalisation and health-related 
costs.21 This topic is addressed in this issue of the HJC 
in an interesting original research article by Fanourg-
iakis et al, entitled “Complications related to cardiac 
rhythm management devices (CRMD’s) therapy and 
their financial implication: a prospective single-cen-
ter two-year survey”.22 In this study, the authors focus 
on the complication rates of cardiac rhythm manage-
ment devices and on the additional costs attributable 
to these complications. After an extended follow up 
(2 years) of 464 patients, a relatively low complication 
rate was recorded, emphasising the cost-effective-
ness of cardiac rhythm management devices, at least 
in well organised, certified high volume centres. In 
line with this evidence, Andrikopoulos, in an editorial 
comment,23 underscores the discrepancy between the 
ample medical data concerning the usefulness of car-
diac rhythm management devices and the noticeable 
lack of evidence concerning the health-related costs 
of these devices, concluding that a nationwide registry 
of complications and additional costs must be imple-
mented. With regard to the implementation of novel 
interventional techniques for the management of ar-
rhythmia related conditions Tzeis et al present a case 
series of cavotricuspid isthmus-dependent flutter, 
treated using an 8-mm ablation catheter equipped 
with a mini electrode.24
At this point we have to observe that, during the 
last decades, advances in cardiology have not been 
limited only to intervention techniques and device 
improvement, but have also encompassed imaging 
modalities and capabilities. Strong evidence for this 
is provided by Nemes et al, in their article entitled 
“Left atrial volumetric and strain analysis by three-
dimensional speckle-tracking echocardiography in 
noncompaction cardiomyopathy: results from the 
MAGYAR-Path study”.25 The article focuses on the 
left atrial function of patients with noncompaction 
cardiomyopathy, which is typically characterised by 
ventricular dysfunction, thromboembolic events and 
arrhythmias. By using novel echocardiographic tech-
niques, such as three-dimensional speckle-tracking 
echocardiography of the left atrium, the authors con-
clude that, as in other cardiomyopathies, noncom-
paction cardiomyopathy is not limited only to the left 
ventricle, but also affects left atrial function. Inter-
estingly, in a related editorial comment, “The pivot-
al role of studying the left atrium by speckle tracking 
in heart failure”,26 Parthenakis and Vardas highlight 
the importance of three-dimensional speckle-tracking 
echocardiography for assessment of the left atrium, 
as the two-dimensional technique seems to be an un-
reliable and non-reproducible tool. In addition, they 
emphasise the importance of left atrial reservoir func-
tion, as it is associated with the prognosis of patients 
with noncompaction cardiomyopathy.
The topics in this issue of the HJC cover a broad 
field, with interesting cardiovascular themes, and the 
Editor of the HJC hopes that readers of the journal 
will positively evaluate our efforts to promote cardi-
ologists’ continuing medical education.
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